Gyre Therapeutics (GYRE) Other Accumulated Expenses (2011 - 2026)

Gyre Therapeutics (GYRE) has 16 years of Other Accumulated Expenses data on file, last reported at $226000.0 in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $226000.0, down 0.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $226000.0 (down 0.88% YoY), and the FY2025 annual result was $227000.0, changed 0.0% from the prior year.
• Other Accumulated Expenses steadied at $226000.0 in Q1 2026 per GYRE's latest filing, from $227000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $4.4 million in Q1 2022 and troughed at $118000.0 in Q4 2022.
• A 5-year average of $957176.5 and a median of $743000.0 in 2023 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses sank 97.77% in 2022, then jumped 1060.17% in 2023.
• A 5-year view of Other Accumulated Expenses shows it stood at $118000.0 in 2022, then jumped by 1060.17% to $1.4 million in 2023, then slumped by 83.42% to $227000.0 in 2024, then changed by 0.0% to $227000.0 in 2025, then slipped by 0.44% to $226000.0 in 2026.
• Business Quant data shows GYRE's Other Accumulated Expenses at $226000.0 in Q1 2026, $227000.0 in Q4 2025, and $228000.0 in Q3 2025.